Fig. 1: Klotho induces platelet activation in the blood and increases circulating platelet factors.
a, Paradigm for plasma proteomics profiling. Young mice (male, age 4 months) were treated with either vehicle (Veh) (n = 10 mice) or klotho (n = 9 mice) (s.c., 10 μg kg−1) followed by plasma proteomics analysis. b, Percentage of alternations among arms during exploration of the Y maze. Young mice (male, age 4 months, n = 9 mice per group) were treated with either Veh or klotho. *P = 0.014 (two-tailed t-test). c, Plasma proteomics by mass spectrometry analysis 4 h after treatment with Veh or klotho identified six differentially expressed proteins (Q < 0.05, dashed horizontal line; and fold change >2, dashed vertical line). d, Canonical functions of top six differentially expressed plasma proteins following klotho treatment (Q < 0.05 and fold change >2). e, Paradigm for measuring platelet activation. Young mice (male, age 5 months, n = 8–9 mice per group) were treated with either Veh or klotho (s.c., 10 μg kg−1) followed by platelet isolation from whole blood and then platelet activation analysis by FACS with markers CD61 and CD62P. f, Flow cytometry plots from FACS showing platelet populations. The upper graphs show density plots of the platelets, gated by side scatter (SSC) (for granularity) and CD61 positivity. The lower graphs show dot plots of the percentage activated (CD61 and CD62P-positive) and resting (CD61-positive only) platelets. g, Quantification of activated platelets in young mice following treatment with Veh (n = 9 mice) or klotho (n = 8 mice). *P = 0.014 (two-tailed t-test). h, Quantification of platelets counts in young mice following treatment with Veh (n = 9 mice) or klotho (n = 8 mice). Data are presented as mean ± s.e.m.
